Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	BMJ Publishing Group 2022

Những quyển sách tương tự

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
Bằng: Josef S Smolen, et al.
Được phát hành: (2022-11-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
Bằng: Coates, L, et al.
Được phát hành: (2018)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
Bằng: Coates, LC, et al.
Được phát hành: (2021)

Ixekizumab in the treatment of psoriatic arthritis
Bằng: Yu. L. Korsakova, et al.
Được phát hành: (2024-12-01)

Methotrexate in psoriasis and psoriatic arthritis
Bằng: Coates, L, et al.
Được phát hành: (2020)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
Bằng: Coates, LC, et al.
Được phát hành: (2016)

Measuring outcomes in psoriatic arthritis
Bằng: Ogdie, A, et al.
Được phát hành: (2020)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
Bằng: Weinstein, SM, et al.
Được phát hành: (2021)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
Bằng: Kavanaugh, A, et al.
Được phát hành: (2024)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
Bằng: Miller J, et al.
Được phát hành: (2021-12-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Bằng: Bruce W. Kirkham, et al.
Được phát hành: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
Bằng: P.S. Helliwell
Được phát hành: (2011-09-01)

Psoriatic arthritis
Bằng: FitzGerald, O, et al.
Được phát hành: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Bằng: Ogdie, A, et al.
Được phát hành: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
Bằng: Coates, LC, et al.
Được phát hành: (2021)

What should be the primary target of "treat to target" in psoriatic arthritis?
Bằng: Coates, LC, et al.
Được phát hành: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Bằng: Helliwell, PS, et al.
Được phát hành: (2022)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Bằng: Coates, L, et al.
Được phát hành: (2020)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
Bằng: Gladman, DD, et al.
Được phát hành: (2018)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Bằng: April W. Armstrong, et al.
Được phát hành: (2024-05-01)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Bằng: Atul Deodhar, et al.
Được phát hành: (2023-08-01)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
Bằng: Ye, W, et al.
Được phát hành: (2021)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Bằng: Mease, PJ, et al.
Được phát hành: (2020)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
Bằng: Coates, LC, et al.
Được phát hành: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
Bằng: Mease, P, et al.
Được phát hành: (2017)

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Bằng: April W. Armstrong, et al.
Được phát hành: (2024-07-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Bằng: Coates, L, et al.
Được phát hành: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
Bằng: Orbai, A-M, et al.
Được phát hành: (2019)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
Bằng: A. M. Dadalova, et al.
Được phát hành: (2020-11-01)

Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
Bằng: A. Egeberg, et al.
Được phát hành: (2022-07-01)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
Bằng: Ye, W, et al.
Được phát hành: (2021)

Current concepts and unmet needs in psoriatic arthritis
Bằng: Mahmood, F, et al.
Được phát hành: (2017)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Bằng: Coates, L, et al.
Được phát hành: (2017)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Bằng: Coates, LC, et al.
Được phát hành: (2024)

Psoriatic arthritis: prospects for the future
Bằng: Hackett, S, et al.
Được phát hành: (2022)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
Bằng: Yazji, SM, et al.
Được phát hành: (2025)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
Bằng: Leung, Y-Y, et al.
Được phát hành: (2023)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Bằng: Helliwell, PS, et al.
Được phát hành: (2021)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
Bằng: Coates, LC, et al.
Được phát hành: (2018)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
Bằng: Coates, L, et al.
Được phát hành: (2016)